戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 arding the optimal formulations and doses of aminosalicylates.
2 ther than gradual step-up after failure of 5-aminosalicylates.
3 anced therapies, the AGA suggests stopping 5-aminosalicylates.
4 drug use were 0.82 (95% CI, 0.42-1.61) for 5-aminosalicylates 0.48 (95% CI, 0.15-1.50) for corticoste
5 e odds ratios were 0.8 (95% CI, 0.5-1.1) for aminosalicylates, 0.5 (95% CI, 0.3-0.9) for immunomodula
6  LFTs were less frequently on treatment with aminosalicylates (22.8 vs. 36.6%, P = 0.04).
7 statements focused on 5 main drug classes: 5-aminosalicylate (5-ASA), corticosteroids, immunosuppress
8 mild flares controlled with initiation of 5'-aminosalicylates (5'-ASA), and two patients (6%) require
9  the association between adherence to oral 5-aminosalicylates (5-ASAs) and all-cause costs and health
10 e relationship with CD mortality was 0.7 for aminosalicylates (95% CI, 0.5-1.1), 1.3 (95% CI, 0.9-1.9
11 tions or to anti-inflammatory therapy with 5-aminosalicylates, although a few require corticosteroids
12 local delivery of existing agents, such as 5-aminosalicylate and corticosteroids, and on novel immuno
13 omen with IBD; 31.2% of women discontinued 5-aminosalicylates and 24.6% discontinued azathioprine/6-m
14 o the overall safety of medical therapy with aminosalicylates and immunomodulators during pregnancy.
15 regarding the optimization of treatment with aminosalicylates and the short- and long-term benefits o
16 unomodulator therapy only after failure of 5-aminosalicylates, and (4) role of continuing vs stopping
17 ith moderate-to-severe UC, who have failed 5-aminosalicylates, and have escalated to therapy with imm
18 ents, treatment with oral corticosteroids, 5-aminosalicylates, and other non-biologic immunomodulator
19 seizure model, mesalazine (MSZ) an effective aminosalicylate anti-inflammatory treatment against ulce
20 st to revolutionary) clinical data regarding aminosalicylates, antibiotics, and steroids as inductive
21 dications (eg, sulfasalazine, diazo-bonded 5-aminosalicylates [ASA], mesalamines, and corticosteroids
22  women with IBD, and all prescriptions for 5-aminosalicylates azathioprine/6-mercaptopurine, and cort
23  and in children exposed or not exposed to 5-aminosalicylates, azathioprine/6-mercaptopurine, or cort
24 udesonide, have a greater acute benefit than aminosalicylates, but this benefit does not translate in
25             Although newer preparations of 5-aminosalicylate continue to provide incremental benefits
26 ot responsive to conventional treatment with aminosalicylates, corticosteroids and immune modulators.
27 strate that mesalamine, an anti-inflammatory aminosalicylate, dose-dependently inhibits IL-1-stimulat
28 ent data support the overall safety of the 5-aminosalicylate drugs as well as azothiaprine/6-mercapto
29  group recommended against the use of oral 5-aminosalicylate for induction or maintenance therapy in
30 spite the fact that, aside from a variety of aminosalicylate formulations, no new therapies have been
31 d drugs, except for a 7% decline in use of 5-aminosalicylate in CD and no change in steroid use for C
32 es, and (4) role of continuing vs stopping 5-aminosalicylates in patients being treated with immunomo
33      No consensus was reached on the role of aminosalicylates in treatment of patients with mild dise
34 fter OLT were generally well controlled with aminosalicylates or oral steroids.
35                                        While aminosalicylates remain a cornerstone treatment of elder
36                       Several drugs, such as aminosalicylates, systemic corticosteroids, immunosuppre
37 f those patients most likely to benefit from aminosalicylate therapies, the risks of relapse from usi
38                                              Aminosalicylate therapy accounts for 29% of the costs of
39 the advances and controversies pertaining to aminosalicylate therapy, corticosteroids, cyclosporine,
40               There were 12.7 years (27%) on aminosalicylate therapy, generating $11,467 (29%) in cha
41                              Antibiotics and aminosalicylates were allowed; immunosuppressants and gl
42                                          (3) Aminosalicylates were helpful in the clinical management
43 g the most interesting chemotypes were the 5-aminosalicylates, which docked in two distinct but overl